Lataa...
Cell Signaling Model Connects Vorinostat Pharmacokinetics and Tumor Growth Response in Multiple Myeloma Xenografts
Multiple myeloma is a fatal hematological malignancy with high rates of drug resistance and relapse. Vorinostat, a histone deacetylase inhibitor, has shown promise in enhancing efficacy when combined with current myeloma therapies. In this study, temporal changes of critical proteins and cell prolif...
Tallennettuna:
| Julkaisussa: | CPT Pharmacometrics Syst Pharmacol |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
John Wiley and Sons Inc.
2017
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5702904/ https://ncbi.nlm.nih.gov/pubmed/29045072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12246 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|